Cooperative Agreement 2349466
Award Date
7/15/25
Completion Date
6/30/27
Dollars Obligated
$990K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Cooperative Agreement
Place of Performance
Research Triangle Park, Durham, NC, USA
Similar Awards
Drive Therapeutics, L.L.C. was awarded a $256,000 Project Grant from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to support optimizing assembly of bispecific aptamer therapeutics. The one-year award running from September 2021 through October 2022 will fund Drive Therapeutics' work to advance science and engineering research and innovation leading to breakthrough technologies as well as solutions to national challenges, as outlined...
This Cooperative Agreement award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $1,000,000.00 in funding to Window Therapeutics, Inc. to develop a novel class of antibody-drug conjugates (ADCs) for treating metastatic cancer. The project aims to significantly increase the drug-to-antibody ratio of ADCs, allowing for the use of less toxic, yet more effective, cancer-killing drugs to be delivered directly to tumor cells. The goal is to...
This Cooperative Agreement award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $999,878 to Akttyva Therapeutics, Inc., a small business located in Watertown, MA, to develop an AI-assisted drug discovery platform to identify existing drugs and new chemical entities capable of repairing vascular permeability barriers. The project aims to address unmet clinical needs for conditions like acute respiratory distress...
This Cooperative Agreement award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) provides $998,356 to Revive Biotechnology Inc. to develop an oxygen nanobubble platform technology for treating ischemic retinal diseases. The project aims to secure an Investigational New Drug (IND) indication for the treatment of central retinal artery occlusion (CRAO), a leading cause of sudden vision loss, and then expand the technology to...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Om Therapeutics Inc. will support the development of a system to enable the rapid, scalable, and cost-effective discovery of new medicines using machine learning. The project aims to encapsulate proteins and small molecules in millions of miniaturized compartments to screen for interactions that could identify novel drug candidates. The key innovations include...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Delaqua Pharmaceuticals, Inc. aims to enhance the therapeutic use of hydrophobic drugs through a polymeric micelle approach to drug solubilization. The key objectives are to 1) improve the formulation of spherical micelles for enhanced stability and drug solubilization, 2) perform initial toxicity studies to establish the safety of the platform, and 3) demonstrate...
This Cooperative Agreement award, funded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop a bioprocessing system to isolate and purify therapeutic antibodies directly from cell culture. The $999,998 award to Athem LLC, a minority-owned small business, will enable scaling up a novel nanoparticle-based purification media and an automated prototype system. The goal is to simplify the manufacturing of biologics, reduce...
This $1,000,000 Cooperative Agreement award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program aims to accelerate R&D in the pharmaceutical industry through the development of streamlined machine learning algorithms for small data applications in advanced manufacturing. The project, awarded to Sunthetics Inc., seeks to save time and resources by up to 95% in lead optimization and route scouting during pre-clinical drug development by...
This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $303,864 to Core Biotherapeutics Inc. to develop a platform for discovering therapeutic drugs that can reprogram molecular networks to treat diseases. The project aims to determine the biological laws driving diseases at the molecular network level and create an algorithm to rapidly identify drug targets. The key goals are to demonstrate that oligonucleotide drug...
This Project Grant award, provided by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to advance gene therapy for neurological disorders by developing a scalable and cost-effective manufacturing process for extracellular vesicle (EV)-based therapeutics. The $304,951 award to Neucore Bio, Inc. will fund research to optimize methods for EV isolation, purification, and cargo loading to enhance therapeutic efficacy, with the goal...